Trial Profile
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Apr 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Carboplatin; Dacarbazine; Paclitaxel
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate-037
- Sponsors Bristol-Myers Squibb
- 10 Apr 2022 This trial has been completed in Spain (End Date: 29 Dec 2020), according to European Clinical Trials Database record.
- 23 Mar 2022 Status changed from active, no longer recruiting to completed.
- 01 Nov 2021 Results published in the Value in Health